CV
Pulmonary Embolism Management
search
Pulmonary Embolism Management
, PE Management, Subsegmental Pulmonary Embolism Management
See Also
Pulmonary Embolism
Deep Vein Thrombosis
Thrombophilia
Pulmonary Embolism Risk Factors
Pulmonary Embolism Diagnosis
Pulmonary Embolism Pretest Probability
(
Wells Clinical Prediction Rule for PE
)
Pulmonary Embolism Rule-Out Criteria
(
PERC Rule
)
Pulmonary Embolism Evaluation with Echocardiogram
Pulmonary Embolism Low Probability Evaluation
Pulmonary Embolism Moderate Probability Evaluation
Pulmonary Embolism High Probability Evaluation
Anticoagulation in Thromboembolism
Thrombolysis in Massive Pulmonary Embolism
Bova Score
Pulmonary Embolism Severity Index
(
PESI
)
sPESI
Hestia Criteria
Indications
Deep Vein Thrombosis
(DVT)
Pulmonary Embolism
(PE)
Precautions
Subsegmental
Pulmonary Embolism
Controversy
CT
Chest
has
False Positive
s and
False Negative
s
False Positive Rate
: 26% read initially as positive, were later over-read as negative
Hutchinson (2015) AJR Am J Roentgenol 205(2): 271-7 +PMID:26204274 [PubMed]
False Negative Rate
: 11% read initially as subsegmental, were later over-read as segmental
Pena (2012) J Thromb Haemost 10:496-8 +PMID:22212300 [PubMed]
Factors associated with a true positive sub-segmental
Pulmonary Embolism
High quality imaging
Multiple filling defects
Defects in proximal subsegmental vessels
Same defect on multiple images or views
Filling defect surrounded by contrast
Symptomatic
Pulmonary Embolism
High pretest probability
Unexplained positive
D-Dimer
Subsegmental
Pulmonary Embolism
treatment has mixed results on outcomes
Some studies have shown worse outcomes with subsegmental
Pulmonary Embolism
treatment
Carrier (2010) J Thromb Haemost 8(8): 1716-22 +PMID:20546118 [PubMed]
Other studies have shown subsegmental PE to have as significant outcomes as segmental PE
den Exeter (2013) Blood 122(7):1144-9 +PMID:23736701 [PubMed]
Despite minor nature of subsegmental PE, recurrent
Pulmonary Embolism
may occur without
Anticoagulation
Kligerman (2014) AJR Am J Roentgenol 202(1): 65-73 +PMID:24370130 [PubMed]
Approach
Evaluate for
Deep Vein Thrombosis
with bilateral
Lower Extremity Doppler
Ultrasound
Consider other sources of VTE (
Upper Extremity DVT
, central-line associated DVT)
Evaluate for risk of VTE progression or recurrence
Hospitalized patients
Decreased mobility
Unprovoked VTE
Hypercoagulable
state including cancer
Otherwise unexplained severe symptoms
Poor cardiopulmonary reserve
Consider surveillance instead of
Anticoagulation
if low risk criteria met (grade 2C evidence)
Sub-segmental PE only (or suspicion for
False Positive
) AND
No concurrent DVT AND
No high risk criteria for progression or recurrence
Grading
Severity
High Risk
Pulmonary Embolism
(Massive Pumonary Embolism)
Pulmonary Embolism
AND
Systolic
Blood Pressure
<90 mmHg or >40 mmHg BP drop from baseline for at least 15 minutes OR
Cardiac Arrest
OR
Vasopressor
s required
Intermediate Risk
Pulmonary Embolism
(Submassive
Pulmonary Embolism
)
Pulmonary Embolism
and
Right ventricular dysfunction (RV Strain)
Serum
Troponin
elevation or
ntBNP
>900 pg/ml or (BNP >90 pg/ml) or
Echocardiogram
with right ventricular dilation or hypokinesis
Low Risk
Pulmonary Embolism
Pulmonary Embolism
and
Normal right ventricular function and
Hemodynamically stable
Management
Acute Stabilization
Correct
Hypoxia
on presentation
Hypoxia
increases shunting, V/Q mismatch and greater right heart strain
Supplemental Oxygen
Refractory
Hypoxia
options
High Flow Nasal Cannula
Pulmonary dilators (inhaled nitric oxide or epoprostenol)
Avoid
Positive Pressure Ventilation
(
BiPap
,
CPAP
,
Mechanical Ventilation
) if possible
Positive pressure may worsen right heart strain
Exercise
caution with
PEEP
(start low at 5 mmHg)
Intubation and RSI if needed should be performed with optimized first pass success
Hypoxic patient will have little reserve and easily decompensate
Correct
Hypotension
(target >90 mmHg)
Small fluid challenges (e.g. 250 ml aliquots) are preferred to avoid further RV strain
Consider
Norepinephrine
for refractory
Hypotension
Management
Massive Pumonary Embolism (Severe cardiovascular compromise)
See
Pulmonary Embolism Evaluation with Echocardiogram
Indications (see grading above)
Massive Pumonary Embolism
Systemic
Hypotension
and shock (or
Cardiac Arrest
)
Systolic
Blood Pressure
<90 mmHg for 15 min (or
Vasopressor
s needed)
Right ventricular
Heart Failure
Submassive
Pulmonary Embolism
Right ventricular dysfunction or
Heart Failure
Controversial for
Thrombolytic
use (evaluate on a case by case basis)
Evidence as of 2017 does not support
Thrombolytic
use for submassive PE
See
Thrombolysis in Massive Pulmonary Embolism
Reviews benefits and risks of
Thrombolysis
in Intermediate Risk PE
Intervention options (includes
Anticoagulation
as above)
Thrombolytic
Therapy
Confirm no
Thrombolytic Contraindication
s
See
Thrombolysis in Massive Pulmonary Embolism
Surgical embolectomy
Alternative management in massive PE when
Thrombolysis
is contraindicated or has failed
Gulba (1994) Lancet 343:576-7 [PubMed]
Intervention Radiology
, catheter directed
Thrombolysis
Uses 75% less
Thrombolytic
than peripheral infusions with lower risk of bleeding and similar mortality
Variable evidence and some studies have shown benefit while others have not
Kuo (2015) Chest 148(3): 667-73 [PubMed]
Piazza (2015) JACC Cardiovasc Interv 8(10): 1382-92 +PMID: 26315743 [PubMed]
Other measures
Avoid intubation if possible
Intubation and ventilation is challenging to manage in
Pulmonary Embolism
VA-ECMO
(
Extracorporeal Membrane Oxygenation
)
Indicated in hemodynamic instability and
Cardiogenic Shock
refractory to other measures
Best outcomes in massive
Pulmonary Embolism
are with early use of
ECMO
Consider pulmonary vasodilation agents
See
Pulmonary Arterial Hypertension Crisis
Right
Ventricular Afterload
optimization (decrease pulmonary vascular resistance)
These agents may exacerbate
Left Ventricular Failure
Agents
Nitroglycerin
1 mg/ml inhaled/nebulized 5 mg (5 ml) over 15 minutes OR
Inhaled Nitric Oxide (20 ppm)
Advantages: No systemic effects and improves V-Q mismatch
Risk of rebound, severe
Pulmonary Arterial Hypertension
if abruptly stopped
Vasopressor
s
Initiate early in
Hypotension
References
Mattu and Swaminathan (2020) EM:RAP 20(11):2
Jaff (2011) Circulation 123: 1788-830 [PubMed]
Konstantinides (2017) J Am Coll Cardiol 69(12): 1536-44 +PMID:28335835 [PubMed]
Management
Gene
ral Measures
Consider
Thrombophilia
work-up
See
Thrombophilia
Reserve blood for tests prior to
Anticoagulation
Consider underlying malignancy in unprovoked PE
Bed rest is not necessary
Does not prevent new or fatal PE of bleeding
Trujillo-Santos (2005) 127:1631-6 [PubMed]
Management
Anticoagulation
See
Anticoagulation in Thromboembolism
Consider
Heparin
prior to imaging in high likelihood
Pulmonary Embolism
Reasonable in high risk cases
Lack of study data to support as standard of care
Risk of adverse outcome (i.e. bleeding complications)
Management
Pregnancy
See
Pulmonary Embolism in Pregnancy
Anticoagulation
Low Molecular Weight Heparin
(except for peripartum use of
Unfractionated Heparin
)
Contraindicated agents:
Warfarin
,
Factor Xa Inhibitor
(e.g. Rivoroxaban)
IVC Filter
Indicated for
Pulmonary Embolism
within 4 weeks of estimated delivery date
Thrombolysis
is absolutely contraindicated (EXCEPT in life threatening, massive PE)
Risk of major bleeding 2.6%
Consider in life-threatening massive
Pulmonary Embolism
if not near term
Gartman (2013) Obstet Med 6:105-11 [PubMed]
Disposition
Outpatient Criteria
Inpatient
Anticoagulation
until therapeutic and stable
Inpatient management is default approach unless outpatient management criteria met
Outpatient
Anticoagulation
management consideration (
Exercise
caution)
Precautions
Inpatient management is required for certain conditions
Active cancer
Pregnancy
Pulmonary Embolism
occurred while on therapeutic doses of
Anticoagulation
Oupatient management should only be considered if consistent with local expert opinion
Must be supported by local protocols
Requires patient
Informed Consent
Risk of major bleeding
Risk of death up to 2% (if cancer patients excluded)
Criteria for outpatient management (all criteria should be met)
Patient must be able to comply with outpatient
Anticoagulation
Stable mental status without
Dementia
Medical literacy
Social support
Risk Stratification Tools with low risk assessment
Pulmonary Embolism Severity Index
(
PESI
) Score <66 (Class 1)
As of 2015,
PESI
<86 (low risk) may be reasonable for discharge
Hestia Criteria
negative
See
Hestia Criteria
Bova Score
stage 1 (low risk)
Simplified PESI
(
sPESI
) with no positive criteria (score 0)
Reassuring appearance with normal
Vital Sign
s
Hemodynamically stable and normotensive
No
Hypoxia
(
Oxygen Saturation
>90%)
No intervention needed (e.g. no thromobolysis or embolectomy)
Troponin
normal
No signs of right ventricular strain
Echocardiogram
without right strain pattern (right ventricle dilatation, D-Sign, hypokinesis)
Troponin
Normal
Brain Natriuretic Peptide
(BNP) normal or unchanged from baseline
No contraindicating conditions (cancer, pregnancy)
No significant comorbidities (e.g. chronic lung disease)
No
Anticoagulation
increased risks
Recent significant bleeding, active bleeding or high risk of bleeding
Severe liver disease
Severe renal disease (
Creatinine Clearance
<30 ml/min)
Platelet Count
>70k
History of
Heparin Induced Thrombocytopenia
No intractable pain
Expected need for IV
Analgesic
s >24 hours (e.g. required at least 2 IV doses in ED)
References
Paripati (2023) Crit Dec Emerg Med 37(7): 18-9
Aujesky (2011) Lancet (2011) 378(9785): 41-8 [PubMed]
Otero (2010) Thromb Res 126(1):e1-5 [PubMed]
Vinson (2012) Ann Emerg Med 60(5): 651-62 [PubMed]
Kearon (2016) Chest 149(2): 315-52 [PubMed]
Zondag (2011) J Thromb Haemost 9(8): 1500-7 +PMID:21645235 [PubMed]
Disposition
ED Observation Unit Protocol
Background
In some regions, these low risk patients are discharged home instead of to observation unit
Indications
Low risk
PESI
Score (Class I to II,
PESI
<86) or low risk on
sPESI
or
Bova Score
AND
Hemodynamically stable (normal
Blood Pressure
)
Contraindications to ED observation unit
Right ventricular strain on
Echocardiogram
Troponin I
ncreased
Brain Natriuretic Peptide
(BNP)
New
Hypoxemia
requiring
Oxygen Supplementation
Dyspnea
or increased work of breathing
Extensive DVT into the iliac or pelvic vessels or free floating thrombus
Heart related hospitalization in last 30 days (CHF exacerbation, CAD)
Unable to be compliant with medical regimen (e.g. homeless, chemical abuse)
Diagnostics
Telemetry
Echocardiogram
(consider as evaluation for right heart strain)
Bilateral
Lower Extremity Doppler
Ultrasound
(consider)
Hypercoagulable
state evaluation in unprovoked
Venous Thromboembolism
Anticoagulation
(choose one)
See
Anticoagulation in Thromboembolism
Warfarin
and
Low Molecular Weight Heparin
(e.g.
Lovenox
)
Direct Oral Anticoagulant
or
DOAC
(e.g.
Rivaroxaban
,
Apixaban
,
Edoxaban
)
Low Molecular Weight Heparin
(e.g.
Lovenox
) alone
Indicated in pregnancy or severe
Thrombophilia
(or when
Warfarin
or
DOAC
s contraindicated)
Discharge goals
Systolic
Blood Pressure
>100 mmHg
Heart Rate
<110 bpm
No
Supplemental Oxygen
required
Negative
Troponin
Education
Anticoagulant
safety (
Trauma
prevention, bleeding signs/symptoms)
Anticoagulation
clinic close follow-up (
Warfarin
)
Discharge
Follow-up (e.g. primary care, hematology, cardiology or vascular) within 72 hours
Anticoagulation
clinic follow-up for
Warfarin
within days
Efficacy
Successful discharge home in 75% of cases (25% require hospital admission)
References
Davenport and Baugh (2018) Crit Dec Emerg Med 32(7): 15-24
Bledsoe (2010) Crit Pathw Cardiol 9(4): 212-5 [PubMed]
Prevention
See
DVT Prevention
See
DVT Prophylaxis
See
DVT Prevention in Travelers
Inferior Vena Cava Filter
Indications
Pulmonary Embolism
despite
Anticoagulation
Contraindication to
Anticoagulation
References
Orman and Mattu in Herbert (2015) EM:Rap 15(12): 8-10
Vibhakar (2015) Crit Dec Emerg Med 29(9): 2-8
Kearon (2016) Chest 149(2):315-52 [PubMed]
Konstantinides (2020) Eur Heart J 41(4):543-603 [PubMed]
Wilbur (2012) Am Fam Physician 86(10):913-9 [PubMed]
Type your search phrase here